APW
BMRN icon

Acima Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acima Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-57
Closed -$5K – 270
2019
Q2 		$5K Hold
57
– – ﹤0.01% 217
2019
Q1 		$5K Hold
57
– – ﹤0.01% 216
2018
Q4 		$5K Buy
+57
New +$5.42K ﹤0.01% 227

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Acima Private Wealth's BMRN Position: Q3 2019 in Review

Acima Private Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 57 shares — an estimated $5K sold.

Acima Private Wealth first reported a position in BMRN in Q4 2018 and held it in 3 quarters. The position peaked at $5K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Acima Private Wealth reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Acima Private Wealth sold 57 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $5K.
  • Acima Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Acima Private Wealth's BioMarin Pharmaceuticals position peaked at $5K in Q2 2019.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Acima Private Wealth's 13F filing for Q3 2019, filed 30 Oct 2019.